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poorly appreciated the professional performance of pharmacists. Therefore, 
raising the awareness about the important role of pharmacist in providing public 
health is warranted.  
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OBJECTIVES: To profile the use of an operator in immunobiological 
supplemental health Fortaleza - Brazil, to identify the most prescribed 
therapeutic regimens and costs. METHODS: Cross-sectional study in two 
hospitals accredited service provider, from March to November/2012. Data were 
recorded by medical expertise in computerized management system (Sabius®) 
performed after the medical consultation. Later, these were entered in Microsoft 
Excell 2007 and analyzed by pharmacists auditors. The cost was calculated from 
the value contained in Brasíndice Unit 765, using the Consumer Price Max. The 
doses used for rheumatoid arthritis Etanercept 50 mg, 40 mg Adalimumab, 
abatacept 750 mg, 300 mg infliximab, 560 mg Tocilizimabe, Rituximab 1g and 
Golimumab 50 mg based on a 70 kg adult. RESULTS: We analyzed 64 patients 
with a mean weight 67 kg, of which 70.31% (n = 45) were women aged 30-59 years 
whose most frequent indications were rheumatoid arthritis (n = 33, 51.56%) and 
ankylosing spondylitis (n = 19; 29.69%). The most immunobiological commonly 
prescribed were Infliximab (n = 36; 56.25%), Tocilizimabe (n = 11, 17.19%), 
abatacept, and Rituximab (n = 8; 12, 50%) and golimumab (n = 1, 1.56%). It was 
observed that 67% (n = 43) patients were naïve immunobiological and 33% (n = 
21) initiated with anti-TNF, whereas 61.9% (n = 13) moved into one another with 
immunobiological mechanism of action and 38.1% (n = 8) continued with an 
anti-TNF, changing only the drug. The average cost of treatment/dose first line 
was R$ 6,068.91 and the second line was R$ 9,590.06, resulting in an incremental 
cost/dose of R$ 3,521.16 (36.72%). CONCLUSIONS: Knowledge of costs and 
pharmacotherapeutic profile becomes important for planning strategies aimed at 
streamlining and optimization of these drugs on quality of care.  
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OBJECTIVES: The Royal London Hospital is a teaching hospital in East London, 
UK. We hypothesised that medical patients with multiple co-morbidities and 
complex disease are likely to present with a new diagnosis when re-admitted 
within a month. Further, re-admission within a week is likely to be related to the 
initial diagnosis. METHODS: We conducted a retrospective audit of all non-
elective adult acute medical admissions over a 6 week period during 2012. We 
collected information on patient demographics, ICD-10 diagnosis, length of 
hospital stay, along with readmissions within one week and one month. We 
reviewed the original and subsequent electronic discharge summaries. We 
highlight patient specific and disease specific factors. RESULTS: There were a 
total of 124 readmissions from the original audit (n=859). A large proportion (40%) 
of all readmissions were in the elderly (over the age of 70). There were 73 (59%) 
readmissions within 1 month, and 37 (30%) within a week. Fourteen patients 
(11%) were readmitted within a week, and again within a month. COPD (33%), PE 
(29%), sepsis (26%) and cellulitis (24%) had the highest re-admission rates. Our 
audit points to a 14.4% readmission rate in our cohort. We aim to address the 
precipitating factors in our new physician led ambulatory care clinic. We 
highlight the bed days saved through such a clinic. CONCLUSIONS: Contrary  
to our hypothesis readmissions within a month were related to the original 
diagnosis, interestingly this was less so when re-admitted within a week. Our 
audit has helped highlight the need for better community management  
plans prior to discharge. This has led to closer links with the  
Community Rehabilitation and Support Team (CReST) in order to reduce 
readmission rates.  
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OBJECTIVES: For treatment needs, accompany is limited for ICU patients. A 30-
minute visit a day is allowed for their families. However, mental disturbance 
have been reported in ICUs. Actually, patients suffer from not only diseases but 
also loneliness in the units. The study was conducted to answer the question 
whether ICU patients need to be accompanied? METHODS: A questionnaire 
survey consisting of 3 questions about the attitude to accompanies in ICU was 
conducted in General Hospital of Shenyang Military Area in China. The 3 
questions are: 1) Do you need an accompanier when treated in ICU? (Yes/No); 2) 
If you need, who will be the candidate? (A family member/A paid nursing staff/A 
relative or friend/Anyone available); 3) How long do you need to stay with your 
family members each day in ICU? (Half an hour/One hour/Half a day/All day). 
After repeatability test, the questionnaire was filled by patients randomly 
selected in ICU wards of cardiology and general medical wards from January 1, to 
August 31, 2011. Chi-square tests were used to compare the choices between 
patients from different wards, of different gender and age. RESULTS: 
Repeatabilities for the 3 questions were 0.742, 0.783, and 0.785. Totally, 142 
patients were involved in, including 69 ICU patients and 73 general patients, 117 
males and 25 females, 53 young & middle aged (≤60 )and 89 old ones (>60). Fifty-
seven percent of the patients needed accompaniers in ICU, 86.6% of the patients 
chose family members as the candidates, 74.6% of the patients needed all-day 
accompanies by family members. Percentages of patients needing half-day and 
all-day accompany by family members were higher in ICU and old patients than 
those in general and younger ones(P<0.05). CONCLUSIONS: Patients do need to 
be accompanied in ICU. An all-day accompany by family member is highly 
preferred.  
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OBJECTIVES: Many NHS hospitals have developed an Acute Medicine Unit to 
streamline all non-elective medical admissions. The cost of providing this 
secondary care service is funded by the local primary care team, who in turn 
receive funding from central government. However, teaching hospitals in the 
capitol would also care for a considerable number of international and national 
patients. We sought to examine if health care costs were reimbursed for these 
patients. METHODS: We undertook a retrospective audit of all admissions over a 
6 week period at a central London teaching hospital. We collected patient 
demographics, ICD-10 diagnosis and length of stay. We identified all “out of 
area” patients and calculated costs incurred based on bed days, diagnosis and re-
admission within a month. The ICD-10 codes were converted to cost (HRG) codes 
through the finance office. RESULTS: A total of 864 admissions and 124 
readmissions were analysed. In all 28% (n=242) of admissions were “out of area”. 
This cohort accounted for 25% of bed occupancy, and cost the hospital £390,300. 
Further, 1% (n=8) of patients were of no fixed abode (homeless) and cost £7,200 in 
bed occupancy. The international patients account for 1% (n=6) and cost £4,500 
in bed occupancy. The top 3 presenting complaints with disease management 
costs were; Sickle cell anaemia (n=27-£34,899) chest pain (n=24-£16,757) and 
lower respiratory tract infection (n=19-£69,288). We went on to compare the 
income generated from these admissions on an individual basis. Initial analysis 
point to a deficit in income generated. This has significant implications for the 
financial viability of secondary/tertiary care hospitals in the NHS. 
CONCLUSIONS: Our analysis point to a considerable financial burden from “out 
of area” patients to the capitol’s hospitals. Reducing this financial burden does 
raise clinical and ethical challenges to the receiving hospital.  
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OBJECTIVES: To quantitatively estimate the effect of copayments for 
prescriptions on adherence to medicines in a publicly insured population. 
METHODS: Eight electronic databases and the grey literature were systematically 
searched by one reviewer for relevant articles, along with hand searches of 
references in review articles and the included studies. Studies were included if 
they involved a publicly insured population, an intervention which was the 
introduction of, or an increase in copayment and if the outcome was objectively 
measured adherence (or non-adherence) to medicines. Measures of adherence 
included Proportion of Days Covered and Medication Possession Ratio. Study 
exclusion, data extraction and quality appraisal were carried out by two 
independent reviewers. A random effects model was used to generate the meta-
analysis in RevMan version 5.1. Statistical heterogeneity was assessed using the 
I2 test; p=>0.1 indicated a lack of heterogeneity. RESULTS: Seven out of 41 studies 
met the inclusion criteria. Five studies contributed more than 1 result to the 
meta-analysis. The meta-analysis included 199, 996 people overall; 74, 236 
people in the copayment group and 125,760 people in the non-copayment group. 
Average age was 71.75 years. In the copayment group, (verses the non-
copayment group), the odds ratio for non-adherence was 1.11 (95% CI 1.09-1.14; 
P=<0.00001). An acceptable level of heterogeneity at I2=10%, (p=0.34) was 
observed. CONCLUSIONS: This meta-analysis showed an 11% increased odds of 
non-adherence to medicines in publicly insured populations involved in a 
system where copayments for medicines are necessary. Policy-makers should be 
wary of potential negative clinical outcomes resulting from lack of adherence. 
Unintended economic repercussions of copayments are possible.  
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OBJECTIVES: Hemophilia, a costly yet treatable rare disease, receives 100% 
reimbursement coverage in most developed world and some developing 
countries. The Chinese Ministry of Health announced in 2012 that 20 high-cost 
diseases (including hemophilia) should be prioritized to ease patients’ economic 
burdens. This study aims to understand the current reimbursement landscape 
for hemophilia in China and to explore potential funding mechanisms that could 
be expanded across China to improve reimbursement coverage to meet this 
requirement. METHODS: Hemophilia reimbursement policies of 3 major social 
insurance schemes were collected in 36 cities (provincial capitals and 
municipalities). In-depth interviews were conducted with selected government 
stakeholders to understand the rationale of different policies in different cities 
